Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Xencor
Biotech
Roche drops HER2 bispecific, Xencor-partnered cytokine
Roche has given two early-phase bispecifics the heave-ho, ending work on a HER2xCD3 prospect and an IL-15 candidate it picked up from Xencor.
Nick Paul Taylor
Jan 30, 2025 4:56am
Xencor pulls back from Genentech cancer pact to cut costs
Nov 8, 2023 6:00am
BMS pays Zenas $50M for some rights to ex-Xencor autoimmune drug
Sep 5, 2023 7:29am
Zenas zips up $118M series B to launch phase 3 trial
Nov 8, 2022 11:35am
Xencor culls 2 bispecifics after early-phase data underwhelm
May 6, 2022 8:30am
Xencor sells ex-lead drug to Tesaro founder in backloaded deal
Nov 22, 2021 8:45am
